No Data
Shandong Lukang Pharmaceutical (600789.SH) subsidiary obtained pharmaceutical registration certificate for Ciprofloxacin Hydrochloride Sodium Chloride Injection.
Shandong Lukang Pharmaceutical (600789.SH) announced that recently, its holding subsidiary shandong lukang pharmaceutical group sail special...
Shandong Lukang Pharmaceutical Gets China Nod for Antibiotic
Shandong Lukang Pharmaceutical (600789.SH): The injection of streptomycin hydrochloride has obtained the pharmaceutical registration certificate.
Ge Longhui September 27th | Shandong Lukang Pharmaceutical (600789.SH) announced that the company has received the Drug Registration Certificate (certificate number: 2024S02279) issued by the National Medical Products Administration for the injection of vancomycin hydrochloride (referred to as "the drug"). Vancomycin mainly exerts its bactericidal effect by inhibiting the biosynthesis of the cell wall.
These 4 Measures Indicate That Shandong Lukang PharmaceuticalLtd (SHSE:600789) Is Using Debt Extensively
shandong lukang pharmaceutical (600789.SH): A subsidiary holding company has obtained a supplementary application approval notice for hydrochloride dapoxtine tablets.
On September 24, Shandong Lukang Pharmaceutical (600789.SH) announced that its holding subsidiary Shandong Lukang Pharmaceutical Group Sate Limited (referred to as "Sate Company") has received the approval and issuance of the supplemental drug application approval notice for Dapoxetine Hydrochloride tablets from the National Medical Products Administration, allowing Sate Company to hold the marketing authorization for the above-mentioned drug. Dapoxetine hydrochloride tablets are clinically used to treat premature ejaculation (PE) in men aged 18 to 64 and are currently the only chemically approved drug for treating premature ejaculation (PE). Dapoxetine hydrochloride is the first-line therapeutic drug recommended in both domestic and international "Premature Ejaculation Diagnosis and Treatment Guidelines". Dapoxetine is a
Shandong Lukang Pharmaceutical's 2024 half-year report
Is The Market Rewarding Shandong Lukang Pharmaceutical Co.,Ltd. (SHSE:600789) With A Negative Sentiment As A Result Of Its Mixed Fundamentals?No Data
No Data
